Breztri Aerosphere Now Available in the US for Asthma
AstraZeneca's triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
AstraZeneca's triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
The FDA approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment for acute uncomplicated influenza and prophylaxis in patients 5 years of age and older.
Read MoreRextovy, a 4 mg naloxone medication, will be available for purchase without a prescription at retail stores and online.
Read MoreENA Respiratory received notices of allowance for two US patents covering its innate immune modulators and their application in preventing COPD exacerbations.
Read MoreResearchers discovered manikomycin, a soil-derived peptide that attacks bacteria in a unique way to bypass existing antibiotic resistance.
Read MoreReal-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
Read MoreResearchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read MoreResearchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
Read MoreCombining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read MoreResearchers at Adelaide University developed a lipid-polymer vehicle that improves drug bioavailability and reduces systemic toxicity in preclinical models of lung cancer.
Read MoreFor every 100 children vaccinated against influenza, between nine and 14 cases are prevented, according to Harvard Medical School data.
Read MoreUpdated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.
Read MoreResearchers developed an avian flu vaccine platform that generates immunity in the respiratory tract and bloodstream to combat H5N1.
Read MoreA study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
Read MoreBenralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read MoreEnanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read MoreData from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More